Moxicip Singules Opha Solution 6x0.4 ml

babies: safe. lactating mothers: it is probably unsafe to use during breastfeeding. limited human data suggests that the drug may pass into the breastmilk and harm the baby.
please consult your doctor. pregnancy: it is unsafe to use during pregnancy. although there are limited studies in humans, animal studies have shown harmful effects on the developing baby.
please consult your doctor. driving: it may cause side effects that could affect your ability to drive. alcohol: no interaction found. liver: no interaction found. kidney: no interaction found..

Eye discomfort Dry eye Burning sensation.

MOXICIP is an antibiotic. it works by preventing bacterial infection by stopping the action of a bacterial enzyme (dna-gyrase), preventing bacteria from dividing and repairing..

If you miss a dose of MOXICIP eye ointment, apply the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not apply a double amount to make up for a missed one..

• you should take MOXICIP as prescribed by the doctor. • it is recommended to take on a fixed time.
• hold the tube close to the eye without touching it. gently squeeze the tube and place the medicine inside the lower eyelid.
• don’t stop the medicine too early; this may lead to the survival of some bacteria and increase the chances of returning of infection or worsening of infection..

contraindicated • moxicip + bepridil: concurrent use may increase the risk of qt-interval prolongation • moxicip + cisapride: concurrent use may increase the risk of qt-interval prolongation • moxicip + dronedarone: concurrent use may increase the risk of qt-interval prolongation • moxicip + pimozide: concurrent use may increase the risk of qt-interval prolongation • moxicip + piperaquine: concurrent use may increase the risk of qt-interval prolongation • moxicip + thioridazine: concurrent use may increase the risk of qt-interval prolongation major • moxicip + acarbose: concurrent use may increase the risk of hypoglycaemia or hyperglycemia • moxicip + rasagiline: concurrent use may result in increased rasagiline exposure • moxicip + tamoxifen: concurrent use may increase the risk of qt-interval prolongation.